Dimethyl fumarate for beta-cell preservation
Generic / repurposed
A repurposed oral immunomodulator best known as the multiple-sclerosis drug Tecfidera, now being tested in Chinese phase 3 studies to see whether it can preserve C-peptide in adults with newly diagnosed type 1 diabetes. No T1D efficacy results have been posted yet, so this remains a trial-watch entry.
The scorecard
The randomized phase 3 trial is designed around mixed-meal C-peptide AUC, but no type 1 diabetes efficacy results are posted yet.[1]
Durability is unknown; the trial follows C-peptide after a 24-week intervention but has not reported.[1]
Dimethyl fumarate has an established MS safety label, but carries clinically important risks including lymphopenia and PML warnings, which matter when repurposed for early T1D.[3]
Current T1D studies are adult, recent/new-onset, and require residual beta-cell function; no pediatric, stage-1, or stage-2 prevention data.[1]
Recruiting phase 3 and open-label studies exist, but the T1D evidence base has not crossed from rationale to reported efficacy.[1]
The full picture
Dimethyl fumarate is interesting because it is oral, already manufactured, and immunomodulatory. But the T1D story is still almost entirely prospective: clinical trials are asking whether it can preserve endogenous insulin production after diagnosis, and the answer is not yet known.
Coming soon
ETA · Phase 3 recruiting; primary completion estimated December 2028
- →Randomized phase 3 C-peptide readout in new-onset adult T1D · primary completion estimated December 2028
Sources
- [1]Clinical Study for Dimethyl Fumarate in Preserving Islet Beta-Cell Function in Type 1 Diabetes Mellitus · registry · 2026-03-05
- [2]Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes · registry · 2026-04-23
- [3]TECFIDERA (dimethyl fumarate) prescribing information · regulatory · 2024-01-01